Streptozotocin for metastatic malignant melanoma

Area of Science:

• Oncology
• Medical Oncology
• Cancer Research

Background:

• Malignant melanoma is an aggressive skin cancer.
• Chemotherapy is a common treatment modality for advanced cancers.

Purpose of the Study:

• To evaluate the efficacy of streptozotocin in patients with advanced malignant melanoma.

Main Methods:

• Fourteen patients with advanced malignant melanoma received streptozotocin at 500 mg/m2/day via continuous infusion for 120 hours.

Main Results:

• No objective responses were observed in any of the patients treated.
• The median survival for the entire patient group was 2 months.

Conclusions:

• At the tested dose and schedule, streptozotocin demonstrated no activity against advanced malignant melanoma.
• Further investigation into streptozotocin for this indication is not warranted based on these findings.